ARTICLE | Clinical News
Marizev omarigliptin regulatory update
April 18, 2016 7:00 AM UTC
Merck said it will not submit an NDA to FDA or an MAA to EMA for diabetes candidate Marizev omarigliptin. Merck said the decision was not due to safety or efficacy concerns and that the pharma has dec...